Valuation: 4basebio PLC

Market Cap 81.58M 109M 97.35M 89.99M 153M 10.36B 155M 1.08B 428M 5.42B 409M 401M 17.11B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 86.18M 115M 103M 95.06M 161M 10.94B 164M 1.14B 453M 5.73B 432M 423M 18.08B EV / Sales 2026 *
82.1x
EV / Sales 2027 * 21.7x
Free-Float
38.75%
Yield 2026 *
-
Yield 2027 * -
1 week-0.94%
Current month-6.67%
1 month-6.67%
6 months+3.96%
Current year-14.63%
1 week 500.5
Extreme 500.5
550
1 month 495
Extreme 495
600
Current year 420
Extreme 420
630
1 year 420
Extreme 420
820
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 2026-02-09
Chief Tech/Sci/R&D Officer - 2025-02-28
Chief Operating Officer - 2026-03-11
Director TitleAgeSince
Director/Board Member 48 2020-12-21
Director/Board Member 33 2024-08-07
Chairman 60 2025-07-07
Date Insider Type Main position Quantity % Market Cap. Importance
5/21/26 Buy

Chief Executive Officer

1,863 0.0120%
2/16/26 Buy

Chief Executive Officer

2,650 0.0171%
2/11/26 Buy

Director

3,000 0.0193%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.94%-27.59%-4.98% 109M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average +0.25%+0.20%+42.06%+106.12% 38.2B
Weighted average by Cap. +0.38%+0.55%+48.15%+122.08%

Financials

2026 *2027 *
Net sales 1.05M 1.4M 1.25M 1.16M 1.97M 133M 2M 13.94M 5.51M 69.78M 5.26M 5.16M 220M 5M 6.69M 5.97M 5.52M 9.36M 635M 9.5M 66.38M 26.26M 332M 25.07M 24.56M 1.05B
Net income -18.2M -24.34M -21.72M -20.08M -34.08M -2.31B -34.59M -242M -95.59M -1.21B -91.24M -89.38M -3.82B -
Net Debt 4.6M 6.15M 5.49M 5.07M 8.61M 584M 8.74M 61.07M 24.16M 306M 23.06M 22.59M 965M 27.1M 36.24M 32.34M 29.89M 50.75M 3.44B 51.51M 360M 142M 1.8B 136M 133M 5.68B
Projected Income Statement - Annual - 4basebio PLC
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
26-10-23 GBX 525.00 0.00% 0
26-10-22 GBX 525.00 0.00% 1
26-10-21 GBX 525.00 0.00% 117
26-10-20 GBX 525.00 0.00% 201
26-10-19 GBX 525.00 0.00% 64
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - 4basebio PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.250GBP
Average target price
12.25GBP
Spread / Average Target
+133.33%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - 4basebio PLC